Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
724.34M | 770.88M | 842.68M | 821.68M | 476.25M | Gross Profit |
364.45M | 362.37M | 407.01M | 406.35M | 283.94M | EBIT |
107.29M | -87.82M | 65.75M | 87.97M | 58.30M | EBITDA |
114.28M | -14.36M | -10.66M | -159.63M | 5.23M | Net Income Common Stockholders |
-74.44M | -175.52M | -215.84M | -296.83M | -36.56M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
137.56M | 103.43M | 119.34M | 223.54M | 136.34M | Total Assets |
1.36B | 1.36B | 1.58B | 1.78B | 1.33B | Total Debt |
639.64M | 682.76M | 670.17M | 624.74M | 354.58M | Net Debt |
502.08M | 579.33M | 550.83M | 401.19M | 218.24M | Total Liabilities |
967.18M | 930.40M | 996.01M | 982.73M | 608.37M | Stockholders Equity |
474.85M | 505.69M | 627.04M | 755.55M | 574.45M |
Cash Flow | Free Cash Flow | |||
108.99M | 681.00K | -67.39M | -82.57M | -91.21M | Operating Cash Flow |
132.48M | 58.56M | 18.74M | 14.49M | -10.83M | Investing Cash Flow |
-25.23M | -44.59M | -36.58M | -163.93M | -44.11M | Financing Cash Flow |
-71.48M | -26.91M | -86.64M | 235.00M | 142.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
51 Neutral | $321.22M | ― | -17.34% | ― | -4.38% | 46.68% | |
$734.45M | 15.51 | 4.61% | ― | ― | ― | ||
$652.44M | ― | -25.08% | ― | ― | ― | ||
$1.21B | 24.68 | 2.83% | ― | ― | ― | ||
$753.34M | ― | -12.39% | ― | ― | ― | ||
$1.58B | ― | -31.94% | ― | ― | ― |
Cresco Labs reported strong financial results for the first quarter of 2025, with a revenue of $166 million and an operating cash flow of $30 million. The company emphasized its strategic approach to reducing credit risk and maintaining financial flexibility, ending the quarter with a cash balance of $162 million, the highest in three years. Cresco Labs aims to drive margin expansion and sustainable growth by deploying capital thoughtfully, positioning itself to gain market share and enhance value for stakeholders.
The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Cresco Labs has announced the updated date for its first quarter 2025 earnings release, scheduled for May 30, 2025. The company has completed its financial review with no material changes and plans to discuss the results in a conference call on June 2, 2025. This announcement reflects Cresco Labs’ commitment to transparency and its strategic positioning in the cannabis market, potentially impacting stakeholders positively by reinforcing trust in its financial practices.
The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Cresco Labs has announced the opening of a new Sunnyside dispensary in Chippewa Township, Beaver Falls, Pennsylvania, reinforcing its strong market presence in the state. This expansion highlights Cresco Labs’ strategic focus on deepening its core market presence, particularly in Pennsylvania where it holds a leading position in branded market share. The new location aims to enhance patient service with high-quality products and a superior retail experience, potentially increasing operating leverage and strengthening its industry positioning.
The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Cresco Labs announced the postponement of its first quarter 2025 earnings release and conference call to allow more time for reviewing its interim financial statements. The rescheduling is expected to have implications for stakeholders as the company aims to maintain transparency and compliance with filing requirements, potentially impacting investor confidence and market perception.
Cresco Labs has announced the postponement of its first quarter 2025 earnings release and conference call, originally scheduled for May 9, 2025, to allow more time for reviewing its interim financial statements. The company expects to reschedule the call and file the statements by May 30, 2025. This delay may impact stakeholders’ expectations and the company’s operational transparency, but Cresco remains committed to maintaining its industry leadership and stakeholder trust.
Cresco Labs reported record financial results for 2024, with an operating cash flow of $132 million, marking a 126% increase from the previous year. The company achieved a revenue of $724 million and maintained its leading market share in Illinois, Pennsylvania, and Massachusetts. Despite a net loss of $60 million due to one-time charges, Cresco Labs improved its adjusted EBITDA by 15% year-over-year, reflecting its disciplined strategy and strong market positioning.
Cresco Labs has announced a management services agreement to operate a Tier 3 Cultivation License in Kentucky, marking a significant expansion into the state’s newly launched medical cannabis market. This move positions Cresco Labs as a key player in Kentucky’s burgeoning cannabis industry, with the potential to influence market growth and capitalize on projected revenue increases, reinforcing its strategic expansion and investment in high-return growth opportunities.